Navigation Links
Particle Sciences and Pernix Therapeutics Enter into an Agreement to Develop a Pediatric Dermatology Product
Date:3/21/2012

BETHLEHEM, Pa., March 21, 2012 /PRNewswire/ -- Particle Sciences, Inc., a leading pharmaceutical CRO, today announced that it is developing with Pernix Therapeutics, a specialty pharmaceutical company, a new topical dermatology product for the pediatric market.

Mark Mitchnick, CEO of Particle Sciences, said, "There are multiple treatments for many pediatric skin conditions.  The unmet need is in the delivery of these agents via a more convenient, and improved vehicle.  Particle Sciences is applying advanced drug delivery and formulation technologies to an established pediatric product category.  For parents, this product is designed to be a potentially better and easier to use product."

Cooper Collins, Pernix Therapeutics' President and CEO, said, "We are enthusiastic about working with Particle Sciences for this product candidate, which may be another opportunity to further expand our pediatric product line."

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on emulsions, gels, micro and nano-particulates, drug/device combination products and highly potent compounds across all dosage forms. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.comor contact us at (610) 861-4701 for information.

Contact:  Maureen Mattera, (610) 861-4701, mmattera@particlesciences.com


'/>"/>
SOURCE Particle Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics Drug Delivery Technology
2. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
3. Particle Sciences Hires Robert Gwozdz to Head Oral Formulation
4. Brabender® Pharma USA, Inc. and Particle Sciences Cooperate to Expand Extrusion Capabilities
5. Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities
6. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
7. Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services
8. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
9. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
10. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
11. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent ... as the number one company for hearing aids, ranking it ... fifteen other brands. ... Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, ...
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 19, 2017 , ... Bone Solutions Inc. (BSI), an orthobiologics ... medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with bone ... a critical property for bone health and development. , “We’re excited to bring ...
(Date:9/19/2017)... ... September 19, 2017 , ... Premiere Long Island dental office Gold ... named one of the best dentists in America under age 40 by Incisal Edge ... Every fall, the magazine features the best 40 dentists under the age of 40 ...
(Date:9/19/2017)... ... 19, 2017 , ... Inc. magazine ranked Endo-Systems ... the nation's fastest-growing private companies. The list represents a unique look at the ... and midsized businesses. Endo-Systems is a leading B2B distributor of today’s most scientifically ...
(Date:9/18/2017)... , ... September 18, 2017 , ... TransLuma is a set of dissolving transitions created ... dissolve in or dissolve away the luminance of a scene without the use of keyframes. ... next scene before fully transitioning over. , TransLuma allows editors to gradually dissolve away the ...
(Date:9/18/2017)... CA (PRWEB) , ... September 18, 2017 , ... Cosmetic ... on its website. According to the senior editor of Cosmetic Tow, “Our forum section ... as well as provide answers to other forum members thinking about having cosmetic surgery. ...
Breaking Medicine News(10 mins):